CELLDEX THERAPEUTICS INC (CLDX)
Health Care · biotechnology · NASDAQ
Celldex Therapeutics is a clinical-stage biotechnology firm developing novel monoclonal antibodies and antibody-drug conjugates to treat complex inflammatory and oncology diseases.
What CELLDEX THERAPEUTICS INC does
Celldex Therapeutics is a clinical-stage biotechnology company focused on the development of monoclonal antibodies and antibody-drug conjugates for the treatment of diseases related to inflammation and oncology. The company's pipeline centers on proprietary platform technologies designed to target immune pathways and cell-surface receptors. Its clinical programs address significant unmet medical needs through protein-based therapeutics.
Themes: oncology, inflammatory diseases, biotech R&D
Fundamentals
- Price$40.57 as of 2026-08-24 close
- Market cap$3.2B as of 2026-08-24
- 1-year return+80.6% 2025-08-22 close $22.46 → 2026-08-24 close $40.57
- P/En/a negative earnings
- Net margin-147788.0% as of 2026-08-24
- Gross margin+17.6% as of 2026-08-24
- ROE-52.3% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)-97.3% as of 2026-08-24
- Revenue CAGR (3y)-13.1% SEC XBRL
- Beta1.14 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How CLDX compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
CLDX is not currently in any published Top 10 list. Its scores are below.
Long-term score
39.0 #1356 of 1,605 scored · #158 of 195 in Health Care
Financial health 95th (debt to equity 0) and long-term trend 81st (trading above its 200-day average); weakest is profitability (2nd, operating margin -159627.2%, return on equity -52.3%).
Short-term score
55.5 #408 of 1,698 scored · #86 of 236 in Health Care
Momentum 67th: over the past 3 months this stock beat the market by 29.6 percentage points; trend 66th: a "golden cross" — its 50-day average is above its 200-day; weakest is volume and participation 33rd: trading volume is unusually light — only about 44% of its 30-day average.
Left this list on 24 Aug 2026
- Left 24 Aug 2026: score 55.5, rank 86 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).
- Entered 18 Aug 2026: first selection for this list at rank 9, score 65.6.
Scores as of 24 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 3.
How CELLDEX THERAPEUTICS INC looks technically
CELLDEX THERAPEUTICS INC (CLDX) is trading 31.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 246 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 4 trading days ago (its momentum flipped negative). It made a new 20-day high about 9 trading days ago. Trading volume is unusually light — only about 44% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 31.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +31.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $37.70 | $37.70 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $30.77 | $30.77 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 12 calendar days ago — the swings before that are what the structure reading is measured on | 12 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 45.14. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a five-part sequence in leg 4. | possible three-wave upward correction, complete (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 246 trading days ago — a "golden cross", a bullish long-term signal | 246 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with buyers in control | 26.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30) | 53.7 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($38.88 to $45.14) — its "stochastic" reading is 27 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 27.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 4 trading days ago (its momentum flipped negative) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $45.14 | $45.14 |
|---|---|---|
| From the 52-week high | it is 10.1% below its 52-week high (its highest price of the past year) | -10.1% |
| Above the 52-week low | it is 99.2% above its 52-week low (its lowest price of the past year) | +99.2% |
| Below the 52-week high | it is 10.1% below its highest point of the past year | 10.1% |
| Since a 20-day breakout | it made a new 20-day high about 9 trading days ago | 9 sessions |
| Since a 55-day breakout | it made a new 55-day high about 9 trading days ago | 9 sessions |
| All-time high | its highest closing price on record is $579.70 (set on 2013-10-02) | $579.70 |
| Given back of the 52-week move | over the past year its closes ranged ($20.89 to $44.87), and it has given back roughly a quarter of its rise from last year’s low — 18% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $29.28 to $30.05. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 17.9% |
| From the all-time high | it is 93.0% below its all-time high | -93.0% |
| Nearest price level | it is trading 11.1% below a resistance level at $45.05 — a price it turned at three times since 2024-09-09, most recently on 2026-08-12. Since 2024-08-26 it has 13 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +11.1% |
| All-time low | its lowest closing price on record is $1.50 (set on 2020-03-19) | $1.50 |
| Above the all-time low | it is 2604.7% above its all-time low | +2,605% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 64th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.70 between its high and its low — about 4.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.70 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $36.06 and $45.32 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $36.06 – $40.69 – $45.32 |
| Typical daily range (% of price) | its price moves about 4.2% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.2% |
| Stretch from the 200-day average | it is trading 5.8 daily ranges above its 200-day average price (31.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.8 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 44% of its 30-day average | 0.44× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bearish engulfing | 7 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 7 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-24 0.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.5% |
|---|---|---|
| Open gap | it gapped 3.0% above the previous close 47 sessions ago and has not traded back through the level it left behind at 31.27 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.0% |
| Gap filled | a 5.0% gap down opened on 2026-07-22 has been "filled" 23 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 23 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +1.58% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 11.7 percentage points (the stock gained 15.0% while the market gained 3.3%) | +11.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 29.6 percentage points (the stock gained 32.0% while the market gained 2.4%) | +29.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 52.3 percentage points (the stock gained 63.3% while the market gained 11.1%) | +52.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 62.3 percentage points (the stock gained 80.6% while the market gained 18.3%) | +62.3% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 13% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-17 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.7% of the share price. | +13.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 25% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $32.54 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +24.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $42.19 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | -3.8% |
Price levels it has turned at before
CLDX last closed at $40.57 on 2026-08-24. Since 2024-08-26 it has turned at 13 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $45.05 | Resistance | 11.1% above the last close | turned there three times · 2024-09-09 to 2026-08-12 |
| $34.73 | Support | 14.4% below the last close | turned there twice · 2026-03-23 to 2026-05-08 |
| $31.65 | Support | 22.0% below the last close | turned there four times · 2024-10-14 to 2026-04-29 |
| $29.24 | Support | 27.9% below the last close | turned there three times · 2024-10-28 to 2026-05-19 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $45.14.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
Alternate reading: The same swings also read as a five-part sequence in leg 4, which fails on a close below $40.30.
This reading has stood for 4 trading days, since 2026-08-19.
Read from daily closes as of 2026-08-24.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · MACD just crossed bearish (12/26/9) · in a strong, established uptrend (ADX) · beating the market · Under water since its last earnings report (below the anchored VWAP) · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · volume and relative volume
Based on daily closing prices as of 2026-08-24. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.25 mean, 1=Strong Buy…5=Strong Sell) — 15 analysts
- Mean price target$58.07 range $38.00 – $100.00; median $56.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CLDX
- Consensus EPS estimate-$1.01 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company has a history of losses, is currently unprofitable, and expects to incur significant losses for the foreseeable future as it continues its research and development efforts.","Success is dependent on the clinical development, regulatory approval, and commercialization of its product candidates, which carry a high risk of failure."]
What changed in the latest 10-Q
AI-assisted comparison of CLDX's 10-Q filed 2026-05-07 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-07) adds: 'our ability to commercialize our drug candidates and the growth of the markets for those drug candidates' as a separate bullet point earlier in the risk factors list
- Newer filing adds: 'our ability to develop and commercialize products before competitors that are superior to the alternatives developed by such competitors' appears twice in the risk factors (duplicated)
- Newer filing adds specific enrollment number for CSU Phase 3: '1,939 patients were enrolled—the largest program conducted in antihistamine refractory CSU'
- Newer filing adds: 'including patients with advanced therapy experienced/refractory CSU'
- Newer filing adds: 'and clinically meaningful improvements in quality of life and angioedema' to the 76-week CSU data description
- Newer filing adds: 'We initiated a Phase 3 study in ColdU and SD in December 2025 and enrollment is ongoing' regarding the Phase 3 initiation timing
- Removed:
- Older filing (2025-11-10) reference to 'Annual Report on Form 10-K for the year ended December 31, 2024' changed to 'December 31, 2025' in newer filing
- Older filing's company overview description 'exploring the science of mast cell biology and developing therapeutic antibodies which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases' is simplified in newer filing
- Older filing states 'We initiated Phase 3 studies in chronic spontaneous urticaria (CSU) in July 2024' - newer filing updates this with completion of enrollment announcement from February 2026
- Older filing states 'Kolltan' without full name 'Kolltan Pharmaceuticals, Inc.' - newer filing adds full corporate name
- Older filing's CSU data ends with 'improved quality of life' - newer filing expands to 'clinically meaningful improvements in quality of life and angioedema'
- Older filing's ColdU/SD section begins 'In July 2024, we announced that our Phase 2 study being conducted in two forms of chronic inducible urticaria (CIndU), ColdU and SD, achieved the primary efficacy endpoint...' - newer filing restructures this to reference Phase 3 initiation in December 2025 with Phase 2 data reference deferred
- Reworded:
- Older overview: 'severe inflammatory, allergic, autoimmune and other devastating diseases' changed to newer: 'allergic, inflammatory and autoimmune disorders' (simplified and reordered)
- Older text: 'our ability to commercialize our drug candidates and the growth of the markets for those drug candidates' appears later in older list; moved higher in newer list
- Older reference 'Kolltan' expanded to 'Kolltan Pharmaceuticals, Inc.' in newer filing
- CSU data description: 'improved quality of life' in older filing becomes 'clinically meaningful improvements in quality of life and angioedema' in newer filing
- ColdU/SD description reorganized: older filing leads with Phase 2 achievement details; newer filing leads with Phase 3 initiation in December 2025 and enrollment status
- Notes:
- Text appears truncated at end of both versions; full ColdU/SD section not fully visible in either filing excerpt
- The apparent duplication of 'our ability to develop and commercialize products before competitors that are superior to the alternatives developed by such competitors' in newer filing version may indicate a transcription or formatting issue in the source document
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for CLDX — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding CLDX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 12,166,013
- Reported value $385,905,934
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 1 increased, 3 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CLDX had 7,627,081 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CLDX had 9.71% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.62 days to cover at the same settlement.
- Reported short interest (shares) 7,627,081
- Short interest (% of shares outstanding) 9.71%
- Prior settlement (shares) 7,663,191
- Reported change -0.47%
- Days to cover (reported) 7.62
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Regeneron Pharmaceuticals (REGN)
- Sanofi (SNY)
- Amgen (AMGN)
- Bristol-Myers Squibb (BMY)
- Novartis (NVS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CLDX vs…
CELLDEX THERAPEUTICS INC is found in…
Frequently asked questions
What does CELLDEX THERAPEUTICS INC (CLDX) do?
Celldex Therapeutics is a clinical-stage biotechnology company focused on the development of monoclonal antibodies and antibody-drug conjugates for the treatment of diseases related to inflammation and oncology. The company's pipeline centers on proprietary platform technologies designed to target immune pathways and cell-surface receptors. Its clinical programs address significant unmet medical needs through protein-based therapeutics.
What sector is CELLDEX THERAPEUTICS INC (CLDX) in?
CELLDEX THERAPEUTICS INC (CLDX) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are CELLDEX THERAPEUTICS INC's (CLDX) competitors?
Notable peers of CELLDEX THERAPEUTICS INC (CLDX) include Regeneron Pharmaceuticals, Sanofi, Amgen, Bristol-Myers Squibb and Novartis. This peer set is informational only — not financial advice.
Is CELLDEX THERAPEUTICS INC (CLDX) overbought or oversold right now?
CELLDEX THERAPEUTICS INC (CLDX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 54, in the neutral middle (as of 2026-08-24). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CLDX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.